{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:57:37Z","timestamp":1792713457049,"version":"4.5.0"},"reference-count":48,"publisher":"American Diabetes Association","issue":"7","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:p>Islet transplantation can restore endogenous \u03b2-cell function to subjects with type 1 diabetes. Sixty-five patients received an islet transplant in Edmonton as of 1 November 2004. Their mean age was 42.9 \u00b1 1.2 years, their mean duration of diabetes was 27.1 \u00b1 1.3 years, and 57% were women. The main indication was problematic hypoglycemia. Forty-four patients completed the islet transplant as defined by insulin independence, and three further patients received &amp;gt;16,000 islet equivalents (IE)\/kg but remained on insulin and are deemed complete. Those who became insulin independent received a total of 799,912 \u00b1 30,220 IE (11,910 \u00b1 469 IE\/kg). Five subjects became insulin independent after one transplant. Fifty-two patients had two transplants, and 11 subjects had three transplants. In the completed patients, 5-year follow-up reveals that the majority (\u223c80%) have C-peptide present post\u2013islet transplant, but only a minority (\u223c10%) maintain insulin independence. The median duration of insulin independence was 15 months (interquartile range 6.2\u201325.5). The HbA1c (A1C) level was well controlled in those off insulin (6.4% [6.1\u20136.7]) and in those back on insulin but C-peptide positive (6.7% [5.9\u20137.5]) and higher in those who lost all graft function (9.0% [6.7\u20139.3]) (P &amp;lt; 0.05). Those who resumed insulin therapy did not appear more insulin resistant compared with those off insulin and required half their pretransplant daily dose of insulin but had a lower increment of C-peptide to a standard meal challenge (0.44 \u00b1 0.06 vs. 0.76 \u00b1 0.06 nmol\/l, P &amp;lt; 0.001). The Hypoglycemic score and lability index both improved significantly posttransplant. In the 128 procedures performed, bleeding occurred in 15 and branch portal vein thrombosis in 5 subjects. Complications of immunosuppressive therapy included mouth ulcers, diarrhea, anemia, and ovarian cysts. Of the 47 completed patients, 4 required retinal laser photocoagulation or vitrectomy and 5 patients with microalbuminuria developed macroproteinuria. The need for multiple antihypertensive medications increased from 6% pretransplant to 42% posttransplant, while the use of statin therapy increased from 23 to 83% posttransplant. There was no change in the neurothesiometer scores pre- versus posttransplant. In conclusion, islet transplantation can relieve glucose instability and problems with hypoglycemia. C-peptide secretion was maintained in the majority of subjects for up to 5 years, although most reverted to using some insulin. The results, though promising, still point to the need for further progress in the availability of transplantable islets, improving islet engraftment, preserving islet function, and reducing toxic immunosuppression.<\/jats:p>","DOI":"10.2337\/diabetes.54.7.2060","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T14:04:22Z","timestamp":1173189862000},"page":"2060-2069","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":1397,"title":["Five-Year Follow-Up After Clinical Islet Transplantation"],"prefix":"10.2337","volume":"54","author":[{"given":"Edmond A.","family":"Ryan","sequence":"first","affiliation":[{"name":"Department of Medicine, Clinical Islet Transplant Program, University of Alberta and Capital Health, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breay W.","family":"Paty","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Islet Transplant Program, University of Alberta and Capital Health, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Senior","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Islet Transplant Program, University of Alberta and Capital Health, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bigam","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Islet Transplant Program, University of Alberta and Capital Health, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Alfadhli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Islet Transplant Program, University of Alberta and Capital Health, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman M.","family":"Kneteman","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Islet Transplant Program, University of Alberta and Capital Health, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.T.","family":"Lakey","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Islet Transplant Program, University of Alberta and Capital Health, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M. James","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Islet Transplant Program, University of Alberta and Capital Health, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031208163308900_R1","doi-asserted-by":"crossref","unstructured":"Shapiro AMJ, Lakey JRT, Ryan EA, Korbutt GS, Toth EL, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med\u2008343:230\u2013238,2000","DOI":"10.1056\/NEJM200007273430401"},{"key":"2022031208163308900_R2","doi-asserted-by":"crossref","unstructured":"Markmann JF, Deng S, Huang X, Desai NM, Velidedeoglu EH, Lui C, Frank A, Markmann E, Palanjian M, Brayman K, Wolf B, Bell E, Vitamaniuk M, Doliba N, Matschinsky F, Barker CF, Naji A: Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg\u2008237:741\u2013750,2003","DOI":"10.1097\/01.SLA.0000072110.93780.52"},{"key":"2022031208163308900_R3","doi-asserted-by":"crossref","unstructured":"Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DER, Bluestone JA: Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant\u20084:390\u2013401,2004","DOI":"10.1046\/j.1600-6143.2003.00351.x"},{"key":"2022031208163308900_R4","doi-asserted-by":"crossref","unstructured":"Shapiro AMJ, Hering BJ, Ricordi C: Edmonton\u2019s success has indeed been replicated elsewhere (Letter). Lancet\u2008362:1242,2003","DOI":"10.1016\/S0140-6736(03)14526-6"},{"key":"2022031208163308900_R5","doi-asserted-by":"crossref","unstructured":"Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm S-H, Zhang H-J, Parkey J, Hunter DW, Sutherland DER: Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA\u2008293:830\u2013835,2005","DOI":"10.1001\/jama.293.7.830"},{"key":"2022031208163308900_R6","doi-asserted-by":"crossref","unstructured":"Goss JA, Goodpastor SE, Brunicardi FC, Barth MH, Soltes GD, Garber AJ, Hamilton DJ, Alejandro R, Ricordi C: Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolaton center. Transplantation\u200877:462\u2013466,2004","DOI":"10.1097\/01.TP.0000100397.86756.A3"},{"key":"2022031208163308900_R7","doi-asserted-by":"crossref","unstructured":"Kessler L, Bucher P, Milliat-Guittard L, Benhamou PY, Berney T, Penfornis A, Badet L, Thivolet C, Bayle F, Oberholzer J, Renoult E, Brun MJ, Rifle G, Atlan C, Colin C, Morel P, GRAGIL Group: Influence of islet transportation on pancreatic islet allotransplantation in type 1 diabetic patients with the Swiss-French GRAGIL network. Transplantation\u200877:1301\u20131304,2004","DOI":"10.1097\/01.TP.0000122223.79315.5D"},{"key":"2022031208163308900_R8","doi-asserted-by":"crossref","unstructured":"Sutherland DER, Gruessner A, Hering BJ: \u0392-cell replacement therapy (pancreas and islet transplantation) for treatment of diabetes mellitus: an integrated approach. Endocrinol Metab Clin North Am\u200833:135\u2013148,2004","DOI":"10.1016\/S0889-8529(03)00099-9"},{"key":"2022031208163308900_R9","doi-asserted-by":"crossref","unstructured":"Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AMJ, Vantyghem M-C: Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes\u200853:955\u2013962,2004","DOI":"10.2337\/diabetes.53.4.955"},{"key":"2022031208163308900_R10","doi-asserted-by":"crossref","unstructured":"Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes\u200819:644\u2013655,1970","DOI":"10.2337\/diab.19.9.644"},{"key":"2022031208163308900_R11","doi-asserted-by":"crossref","unstructured":"Linetsky E, Bottino R, Lehmann R, Alejandro R, Inverardi L, Ricordi C: Improved human islet isolation using a new enzyme blend, liberase. Diabetes\u200846:1120\u20131123,1997","DOI":"10.2337\/diabetes.46.7.1120"},{"key":"2022031208163308900_R12","doi-asserted-by":"crossref","unstructured":"Lakey JRT, Warnock GL, Shapiro AMJ, Korbutt GS, Ao Z, Kneteman NM, Rajotte RV: Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant\u20088:285\u2013292,1999","DOI":"10.1177\/096368979900800309"},{"key":"2022031208163308900_R13","doi-asserted-by":"crossref","unstructured":"Ricordi C, Lacy PE, Scharp DW: Automated islet isolation from human pancreas. Diabetes\u200838 (Suppl. 1):140\u2013142,1989","DOI":"10.2337\/diab.38.1.S140"},{"key":"2022031208163308900_R14","doi-asserted-by":"crossref","unstructured":"Tsujimura T, Kuroda Y, Kin T, Avila JG, Rajotte RV, Korbutt GS, Ryan EA, Shapiro AMJ, Lakey JRT: Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution\/perfluorochemical) cold storage method. Transplantation\u200874:1687\u20131691,2002","DOI":"10.1097\/00007890-200212270-00007"},{"key":"2022031208163308900_R15","doi-asserted-by":"crossref","unstructured":"Ricordi C, Gray DW, Hering BJ, Kaufman DB, Warnock GL, Kneteman NM, Lake SP, London NJ, Alejandro R, Zeng Y, Scharp D, Viviani G, Falqui L, Tzakis A, Bretzel R, Federlin K, Pozza G, James RFL, Rajotte R, DiCarlo V, Morris PJ, Sutherland DER, Starzl T, Mintz DH, Lacy P: Islet isolation assessment in man and large animals. Acta Diabetol Lat\u200827:185\u2013195,1990","DOI":"10.1007\/BF02581331"},{"key":"2022031208163308900_R16","doi-asserted-by":"crossref","unstructured":"Baidal DA, Froud T, Ferreira JV, Khan A, Alejandro R, Ricordi C: The bag method for islet cell infusion. Cell Transplant\u200812:809\u2013813,2003","DOI":"10.3727\/000000003108747280"},{"key":"2022031208163308900_R17","doi-asserted-by":"crossref","unstructured":"Sellers MT, McGuire BM, Haustein SV, Bynon JS, Hunt SL, Eckhoff DE: Two-dose daclizumab induction therapy in 209 liver transplants single-center analysis. Transplantation\u200878:1212\u20131217,2004","DOI":"10.1097\/01.TP.0000138100.72757.BA"},{"key":"2022031208163308900_R18","doi-asserted-by":"crossref","unstructured":"Ryan EA, Paty BW, Senior PA, Lakey JRT, Bigam D, Shapiro AMJ: \u0392-score: an assessment of \u0392-cell function after islet transplantation. Diabetes Care\u200828:343\u2013347,2005","DOI":"10.2337\/diacare.28.2.343"},{"key":"2022031208163308900_R19","doi-asserted-by":"crossref","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia\u200828:412\u2013419,1985","DOI":"10.1007\/BF00280883"},{"key":"2022031208163308900_R20","doi-asserted-by":"crossref","unstructured":"Vaccaro O, Masulli M, Cuomo V, Albarosa-Rivellese A, Uusitupa M, Vessby B, Hermansen K, Tapsell L, Riccardi G: Comparative evaluation of simple indices of insulin resistance. Metabolism\u200853:1522\u20131526,2004","DOI":"10.1016\/j.metabol.2004.05.017"},{"key":"2022031208163308900_R21","doi-asserted-by":"crossref","unstructured":"Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Ka\u0308llen R, \u00d8straat \u00d8, Salmela K, Tibell A, Tufveson G, Elgue G, Nilsson Ekdahl K, Korsgren O, Nilsson B: Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet\u2008360:2039\u20132045,2003","DOI":"10.1016\/S0140-6736(02)12020-4"},{"key":"2022031208163308900_R22","doi-asserted-by":"crossref","unstructured":"Bertuzzi F, Marzorati S, Maffi P, Piemonti L, Melzi R, de Taddeo F, Valtolina V, D\u2019Angelo A, di Carlo V, Bonifacio E, Secchi A: Tissue factor and CCL2\/monocyte chemoattractant protein-1 released by human islets affect islet engraftment in type 1 diabetic recipients. J Clin Endocrinol Metab\u200889:5724\u20135728,2004","DOI":"10.1210\/jc.2004-0659"},{"key":"2022031208163308900_R23","doi-asserted-by":"crossref","unstructured":"Ryan EA, Lakey JRT, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AMJ: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes\u200851:2148\u20132157,2002","DOI":"10.2337\/diabetes.51.7.2148"},{"key":"2022031208163308900_R24","doi-asserted-by":"crossref","unstructured":"Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL: \u0392-cell function following human islet transplantation for type 1 diabetes. Diabetes\u200854:100\u2013106,2005","DOI":"10.2337\/diabetes.54.1.100"},{"key":"2022031208163308900_R25","doi-asserted-by":"crossref","unstructured":"Alejandro R, Lehmann R, Ricordi C, Kenyon NS, Angelico MC, Burke G, Esquenazi V, Nery J, Betancourt AE, Kong SS, Miller J: Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes\u200846:1983\u20131989,1997","DOI":"10.2337\/diabetes.46.12.1983"},{"key":"2022031208163308900_R26","doi-asserted-by":"crossref","unstructured":"Robertson RP, Lanz KJ, Sutherland DE, Kendall DM: Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes\u200850:47\u201350,2001","DOI":"10.2337\/diabetes.50.1.47"},{"key":"2022031208163308900_R27","doi-asserted-by":"crossref","unstructured":"Shapiro AM, Gallant HL, Hao EG, Lakey JR, McCready T, Rajotte RV, Yatscoff RW, Kneteman NM: The portal immunosuppressive storm: relevance to islet transplantation. Ther Drug Monit\u200827:35\u201337,2005","DOI":"10.1097\/00007691-200502000-00008"},{"key":"2022031208163308900_R28","doi-asserted-by":"crossref","unstructured":"Desai NM, Goss JA, Deng S, Wolf BA, Markmann E, Palanjian M, Shock AP, Feliciano S, Brunicardi FC, Barker CF, Naji A, Markmann JF: Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?Transplantation\u200876:1623\u20131637,2003","DOI":"10.1097\/01.TP.0000081043.23751.81"},{"key":"2022031208163308900_R29","doi-asserted-by":"crossref","unstructured":"Bell E, Cao X, Moibi JA, Greene SR, Young R, Trucco M, Gao Z, Matschinsky FM, Deng S, Markman JF, Naji A, Wolf BA: Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes\u200852:2731\u20132739,2003","DOI":"10.2337\/diabetes.52.11.2731"},{"key":"2022031208163308900_R30","doi-asserted-by":"crossref","unstructured":"Han D, Xu X, Baidal D, Leith J, Ricordi C, Alejandro R, Kenyon NS: Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes\u200853:2281\u20132290,2004","DOI":"10.2337\/diabetes.53.9.2281"},{"key":"2022031208163308900_R31","doi-asserted-by":"crossref","unstructured":"Henderson JR, Moss MC: A morphometric study of the endocrine and exocrine capillaries of the pancreas. Q J Exp Physiol\u200870:347\u2013356,1985","DOI":"10.1113\/expphysiol.1985.sp002920"},{"key":"2022031208163308900_R32","unstructured":"Like AA: The uptake of exogenous peroxidase by the beta cells of the islets of Langerhans. Am J Pathol\u200859:225\u2013246,1970"},{"key":"2022031208163308900_R33","doi-asserted-by":"crossref","unstructured":"Hirshberg B, Mog S, Patterson N, Leconte J, Harlan DM: Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using Edmonton Protocol immunosuppression. J Clin Endocrinol Metab\u200887:5424\u20135429,2002","DOI":"10.1210\/jc.2002-020684"},{"key":"2022031208163308900_R34","doi-asserted-by":"crossref","unstructured":"Robertson RP: Islet transplantation as a treatment for diabetes: a work in progress. N Engl J Med\u2008350:694\u2013705,2004","DOI":"10.1056\/NEJMra032425"},{"key":"2022031208163308900_R35","doi-asserted-by":"crossref","unstructured":"Paty BW, Ryan EA, Shapiro AMJ, Lakey JRT, Robertson RP: Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes\u200851:3428\u20133434,2002","DOI":"10.2337\/diabetes.51.12.3428"},{"key":"2022031208163308900_R36","doi-asserted-by":"crossref","unstructured":"Brennan DC, Shannon MB, Koch MJ, Polonsky KS, Desai N, Shapiro J: Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. Transplantation\u200878:172\u2013173,2004","DOI":"10.1097\/01.TP.0000128332.71657.EA"},{"key":"2022031208163308900_R37","doi-asserted-by":"crossref","unstructured":"Hirshberg B, Rother KI, Digon BJ 3rd, Lee J, Gaglia JL, Hines K, Read EJ, Chang R, Wood BJ, Harlan DM: Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression. Diabetes Care\u200826:3288\u20133295,2003","DOI":"10.2337\/diacare.26.12.3288"},{"key":"2022031208163308900_R38","doi-asserted-by":"crossref","unstructured":"Bertuzzi F, Grohovaz F, Maffi P, Caumo A, Aldrighetti L, Nano R, Hengster P, Calori G, Di Carlo V, Bonifacio E, Secchi A: Successful transplantation of human islets in recipients bearing a kidney graft. Diabetologia\u200845:77\u201384,2002","DOI":"10.1007\/s125-002-8247-2"},{"key":"2022031208163308900_R39","doi-asserted-by":"crossref","unstructured":"Oberholzer J, Triponez F, Mage R, Andereggen E, Bu\u0308hler L, Cre\u0301tin N, Fournier B, Goumaz C, Lou J, Philippe J, Morel P: Human islet transplantation. Transplantation\u20086:1115\u20131123,2000","DOI":"10.1097\/00007890-200003270-00016"},{"key":"2022031208163308900_R40","doi-asserted-by":"crossref","unstructured":"Clayton HA, Davies JE, Pollard CA, White SA, Musto PP, Dennison AR: Pancreatectomy with islet autotransplantation for the treatment of severe chronic pancreatitis: the first 40 patients at the Leicester general hospital. Transplantation\u200876:92\u201398,2003","DOI":"10.1097\/01.TP.0000054618.03927.70"},{"key":"2022031208163308900_R41","doi-asserted-by":"crossref","unstructured":"Gupta V, Wahoff DC, Rooney DP, Poitout V, Sutherland DER, Kendall DM, Robertson RP: The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. Diabetes\u200846:28\u201333,1997","DOI":"10.2337\/diabetes.46.1.28"},{"key":"2022031208163308900_R42","doi-asserted-by":"crossref","unstructured":"Cure P, Pileggi A, Froud T, Norris PM, Baidal DA, Cornejo A, Hafiz MM, Ponte G, Poggioli R, Yu J, Saab A, Selvaggi G, Ricordi C, Alejandro R: Alterations of the female reproductive system in recipients of islet grafts. Transplantation\u200878:1576\u20131581,2004","DOI":"10.1097\/01.TP.0000147301.41864.C0"},{"key":"2022031208163308900_R43","doi-asserted-by":"crossref","unstructured":"Aboujaoude W, Milgrom ML, Govani MV: Lymphedema associated with sirolimus in renal transplant recipients. Transplantation\u200877:1094\u20131096,2004","DOI":"10.1097\/01.TP.0000118406.01509.75"},{"key":"2022031208163308900_R44","doi-asserted-by":"crossref","unstructured":"Senior PA, Shapiro AMJ, Ackerman TE, Ryan EA, Paty BW, Bhargava R: Magnetic resonance-defined perinephric edema after clinical islet transplantation: a benign finding associated with mild renal impairment. Transplantation\u200878:945\u2013948,2004","DOI":"10.1097\/01.TP.0000134971.15093.07"},{"key":"2022031208163308900_R45","doi-asserted-by":"crossref","unstructured":"Markmann JF, Rosen M, Siegelman ES, Soulen MC, Deng S, Barker CF, Naji A: Magnetic resonance defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival?Diabetes\u200852:1591\u20131594,2003","DOI":"10.2337\/diabetes.52.7.1591"},{"key":"2022031208163308900_R46","doi-asserted-by":"crossref","unstructured":"Bhargava R, Senior PA, Ackerman TE, Ryan EA, Paty BW, Lakey JRT, Shapiro AMJ: Prevalence of hepatic steatosis after islet transplantation and its relationship to graft function. Diabetes\u200853:1311\u20131317,2004","DOI":"10.2337\/diabetes.53.5.1311"},{"key":"2022031208163308900_R47","doi-asserted-by":"crossref","unstructured":"Ryan EA, Lakey JRT, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AMJ: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. Diabetes\u200850:710\u2013719,2001","DOI":"10.2337\/diabetes.50.4.710"},{"key":"2022031208163308900_R48","doi-asserted-by":"crossref","unstructured":"Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G: Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not with tacrolimus. Liver Transpl\u20087:401\u2013408,2001","DOI":"10.1053\/jlts.2001.23916"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/54\/7\/2060\/382576\/zdb00705002060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/54\/7\/2060\/382576\/zdb00705002060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:26:56Z","timestamp":1667392016000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/54\/7\/2060\/12547\/Five-Year-Follow-Up-After-Clinical-Islet"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.54.7.2060","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}